-+ 0.00%
-+ 0.00%
-+ 0.00%

Market Chatter: Novartis' Spinal Muscular Atrophy Treatment Linked to Tumors in Children

MT Newswires·11/06/2026 04:56:03
Listen to the news
04:56 AM EST, 11/06/2026 (MT Newswires) -- Novartis (NOVN.SW) said testing has linked tumors in two children to Zolgensma, the spinal muscular atrophy treatment they previously took, Bloomberg News reported Friday, citing a company statement. The Swiss drugmaker said it has received nine tumor reports since the therapy was approved in 2019 for children under two with the condition. It added that the two patients with confirmed cases have undergone treatment and continue to be monitored. Novartis did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)